Category: Press Releases
COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer
COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis
CBRE Arranges Expansion Lease for Cour Pharmaceuticals
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy
U.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC)
FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals
Today, COUR Pharma announced the U.S. Food and Drug Administration accepted its […]
COUR’s intracellular T-cell reprograming leads to a reduction to anti-drug and neutralizing antibodies
Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
Late-breaking data presented from a Phase 2a trial at UEG Week 2019, […]